Form 4: Jasper Therapeutics Director Judith Shizuru Granted Stock Options

Judith Shizuru, a director at Jasper Therapeutics, was granted stock options to purchase 7,500 shares of voting common stock at an exercise price of $25.41, exercisable starting June 6, 2025.

Summary

• Judith Shizuru, a director of Jasper Therapeutics, Inc., filed a Form 4 on June 10, 2024, reporting a transaction.
• The transaction involved the grant of stock options to Ms. Shizuru on June 6, 2024.
• Ms. Shizuru received options to purchase 7,500 shares of Jasper Therapeutics' voting common stock at an exercise price of $25.41 per share.
• The options become exercisable on June 6, 2025, and expire on June 6, 2034.
• Ms. Shizuru also granted a Power of Attorney to Ronald Martell and Herb Cross, allowing them to execute and file Forms 3, 4, 5, and 144 on her behalf.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to stock option grants, which is generally neutral. It indicates standard compensation practices.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry, similar to companies like Sangamo Therapeutics and CRISPR Therapeutics.
• The vesting schedule and exercise price are typical for stock option grants to directors.

Key Dates